Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease

被引：87
|
作者：
Al-Homsi, Ahmad Samer [1 ,2 ]
Roy, Tara S. [1 ]
Cole, Kelli [1 ]
Feng, Yuxin [1 ]
Duffner, Ulrich [2 ,3 ]
机构：
[1] Spectrum Hlth, Blood & Marrow Transplantat, Grand Rapids, MI 49503 USA
[2] Michigan State Univ, Coll Human Med, Dept Med, Grand Rapids, MI USA
[3] Helen DeVos Children Hosp, Grand Rapids, MI USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 04期
关键词：
Cyclophosphamide; GVHD; GVHD prevention; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; T-CELLS; PERIPHERAL-BLOOD; HEMATOLOGIC MALIGNANCIES; HAPLOIDENTICAL TRANSPLANTATION; TOLERANCE; PROPHYLAXIS; INDUCTION; IMMUNOTHERAPY;
D O I：
10.1016/j.bbmt.2014.08.014
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Cyclophosphamide's lack of hematopoietic stem cell toxicity and its unique effects on the immune system have prompted several investigators to explore its potential for the prevention of graft-versus-host disease (GVHD). In haploidentical hematopoietic stem cell transplants, post-transplant cyclophosphamide together with standard prophylaxis reduces the incidence of GVHD to acceptable rates without the need for T cell depletion. In matched related and unrelated donor settings, cyclophosphamide alone has produced encouraging results. In particular, the low incidence of chronic GVHD is noteworthy. Here, we present a review of the current understanding of the mechanism of action of post-transplant cyclophosphamide and summarize the clinical data on its use for the prevention of GVHD. (C) 2015 American Society for Blood and Marrow Transplantation.
引用
收藏
页码：604 / 611
页数：8
相关论文
共 50 条
  • [41] Post-Transplant Cyclophosphamide and Thymoglobulin, a Graft-Versus-Host Disease Prophylaxis in Matched Sibling Donor Peripheral Blood Stem Cell Transplantations
    Kunacheewa, Chutima
    Owattanapanish, Weerapat
    Jirabanditsakul, Chutirat
    Issaragrisil, Surapol
    CELL TRANSPLANTATION, 2020, 29
  • [42] Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model
    Adhikary, Sam R.
    Cuthbertson, Peter
    Nicholson, Leigh
    Bird, Katrina M.
    Sligar, Chloe
    Hu, Min
    O'Connell, Philip J.
    Sluyter, Ronald
    Alexander, Stephen, I
    Watson, Debbie
    IMMUNOLOGY, 2021, 164 (02) : 332 - 347
  • [43] Risk Factors for Graft-Versus-Host Disease (GVHD) in Haploidentical Hematopoietic Cell Transplantation (HCT) Using Post-Transplant Cyclophosphamide (PTCy)
    Rashidi, Armin
    Hamilton, Betty K.
    Wang, Tao
    Hemmer, Michael T.
    Spellman, Stephen R.
    Alousi, Amin M.
    Jagasia, Madan
    Pidala, Joseph A.
    Arora, Mukta
    Im, Annie P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [44] High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention
    Holtzman, Noa G.
    Curtis, Lauren M.
    Salit, Rachel B.
    Shaffer, Brian C.
    Pirsl, Filip
    Ostojic, Alen
    Steinberg, Seth M.
    Schulz, Eduard
    Wilder, Jennifer S.
    Hughes, Thomas E.
    Rose, Jeremy
    Memon, Sarfraz
    Korngold, Robert
    Gea-Banacloche, Juan C.
    Fowler, Daniel H.
    Hakim, Frances T.
    Gress, Ronald E.
    Bishop, Michael R.
    Pavletic, Steven Z.
    BLOOD ADVANCES, 2024, 8 (16) : 4294 - 4310
  • [45] Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice
    Cuthbertson, Peter
    Button, Amy
    Sligar, Chloe
    Elhage, Amal
    Vine, Kara L.
    Watson, Debbie
    Sluyter, Ronald
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [46] Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide
    McCurdy, Shannon R.
    Kanakry, Christopher G.
    Tsai, Hua-Ling
    Kasamon, Yvette L.
    Showel, Margaret M.
    Bolanos-Meade, Javier
    Huff, Carol Ann
    Borrello, Ivan
    Matsui, William H.
    Brodsky, Robert A.
    Ambinder, Richard F.
    Bettinotti, Maria P.
    Fuchs, Ephraim J.
    Rosner, Gary L.
    Jones, Richard J.
    Luznik, Leo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (02) : 343 - 352
  • [47] CYCLOSPORINE (CSA) VERSUS CYCLOPHOSPHAMIDE (CY) - PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD)
    SANTOS, GW
    BROOKMEYER, R
    SARAL, R
    TUTSCHKA, PJ
    EXPERIMENTAL HEMATOLOGY, 1985, 13 (05) : 427 - 427
  • [48] The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant
    Saliba, Rima M.
    Marcoux, Curtis
    Alousi, Amin
    Rondon, Gabriela
    Chen, Julianne
    Daher, May
    Champlin, Richard E.
    Rezvani, Katayoun
    Shpall, Elizabeth J.
    Mehta, Rohtesh S.
    BLOOD, 2023, 142
  • [49] Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease
    Navajas, Eduardo V.
    Krema, Hatem
    Hammoudi, Dena S.
    Lipton, Jeffrey H.
    Simpson, E. Rand
    Boyd, Shelley
    Easterbrook, Michael
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2015, 50 (06): : 442 - 450
  • [50] The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML
    Avichai Shimoni
    Myriam Labopin
    Emanuele Angelucci
    Didier Blaise
    Fabio Ciceri
    Yener Koc
    Zafer Gülbas
    J. L. Diez-Martin
    Benedetto Bruno
    Luca Castagna
    Massimo Martino
    Montserrat Rovira
    Mohamad Mohty
    Arnon Nagler
    Bone Marrow Transplantation, 2022, 57 : 384 - 390
12345